We identified potential downstream effectors of SOX11 in DCIS, which adds new biological information that may contribute to a better understanding of the pathology and the identification of suitable treatment options for patients with breast lesions that express SOX11. Here, SOX11 is linked to ductal breast carcinoma in situ.